Hermes Biosciences Raises Seed Funding to Make Extracellular Vesicles a Practical Tool for Precision Medicine
Hermes Biosciences, a life science tools company developing a benchtop, hands-off system for the isolation of extracellular vesicles (EVs), today announced it raised a Seed financing round to deliver its first commercial instrument in 2026, aimed at clinical researchers across academia, Pharma, and clinical customers who require standardized, scalable workflows. The round was led by Genoa Ventures, with participation from Paladin Capital Group and Vertical Venture Partners. Pre-Seed capital and company formation support were also provided by Genoa’s venture studio, General Inception.
